Healthcare provider profile · identity verified

Richard Hammoud, MD

Allopathic & Osteopathic Physicians|Internal Medicine · DEARBORN, MI · NPI 1255330767

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Richard Hammoud, MD received $1,029.95 in general payments during 2025 across 35 reported records.

CeQur Corporation accounted for 41.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 380 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$1,029.95

35 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
CeQur Corporation	Unresolved — no canonical attribution shown	$422.48	41.0%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$394.02	38.3%	20	2025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$198.67	19.3%	13	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$14.78	1.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$1,029.95	35

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CeQur Simplicity Normalized: cequr simplicity	Device	CeQur Corporation	$422.48	1	2025
Source payment records 2025-02-13 · CeQur Corporation · $422.48 · Open Payments source
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$198.67	13	2025
Source payment records 2025-01-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.07 · Open Payments source 2025-01-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.44 · Open Payments source 2025-02-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.10 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.37 · Open Payments source 2025-02-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.09 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.01 · Open Payments source 2025-03-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.67 · Open Payments source 2025-03-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.38 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.60 · Open Payments source 2025-05-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.98 · Open Payments source 2025-10-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.84 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.20 · Open Payments source 2025-12-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.92 · Open Payments source
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$14.89	1	2025
Source payment records 2025-11-17 · AstraZeneca Pharmaceuticals LP · $14.89 · Open Payments source
ELIQUIS Normalized: eliquis	Drug	E.R. Squibb & Sons, L.L.C.	$14.78	1	2025
Source payment records 2025-07-30 · E.R. Squibb & Sons, L.L.C. · $14.78 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	380	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	50	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713	Eliquis · 2024 Exact normalized brand match · 1 Part D row	380	67

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	952	117
Atorvastatin Calcium	Atorvastatin Calcium	941	216
Amlodipine Besylate	Amlodipine Besylate	902	190
Losartan Potassium	Losartan Potassium	549	114
Omeprazole	Omeprazole	545	130
Lisinopril	Lisinopril	531	111
Gabapentin	Gabapentin	488	78
Levothyroxine Sodium	Levothyroxine Sodium	460	96
Metformin Hcl	Metformin Hcl	444	89
Albuterol Sulfate Hfa	Albuterol Sulfate	405	111
Pantoprazole Sodium	Pantoprazole Sodium	404	89
Alprazolam	Alprazolam	393	51
Eliquis	Apixaban	380	67
Tamsulosin Hcl	Tamsulosin Hcl	378	72
Metoprolol Tartrate	Metoprolol Tartrate	340	90
Ibuprofen	Ibuprofen	306	81
Furosemide	Furosemide	290	76
Hydralazine Hcl	Hydralazine Hcl	261	72
Fluticasone Propionate	Fluticasone Propionate	256	69
Clopidogrel	Clopidogrel Bisulfate	246	63
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	246	47
Metoprolol Succinate	Metoprolol Succinate	238	59
Carvedilol	Carvedilol	233	55
Ondansetron Hcl	Ondansetron Hcl	207	49
Simvastatin	Simvastatin	205	46
Sertraline Hcl	Sertraline Hcl	203	45
Trazodone Hcl	Trazodone Hcl	199	44
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	191	37
Hydrochlorothiazide	Hydrochlorothiazide	181	37
Diazepam	Diazepam	178	22
Tramadol Hcl	Tramadol Hcl	174	43
Azithromycin	Azithromycin	169	110
Ozempic	Semaglutide	153	29
Zolpidem Tartrate	Zolpidem Tartrate	152	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	150	39
Atenolol	Atenolol	148	34
Rosuvastatin Calcium	Rosuvastatin Calcium	148	30
Diclofenac Sodium	Diclofenac Sodium	146	42
Potassium Chloride	Potassium Chloride	134	38
Ventolin Hfa	Albuterol Sulfate	132	38
Famotidine	Famotidine	127	40
Jardiance	Empagliflozin	125	21
Acetaminophen-Codeine	Acetaminophen With Codeine	121	26
Januvia	Sitagliptin Phosphate	121	27
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	118	19
Donepezil Hcl	Donepezil Hcl	117	32
Methocarbamol	Methocarbamol	116	35
Methylprednisolone	Methylprednisolone	113	83
Triamcinolone Acetonide	Triamcinolone Acetonide	110	38
Prednisone	Prednisone	106	60
Montelukast Sodium	Montelukast Sodium	104	22
Pregabalin	Pregabalin	103	20
Allopurinol	Allopurinol	102	19
Mirtazapine	Mirtazapine	102	26
Glimepiride	Glimepiride	94	18
Buspirone Hcl	Buspirone Hcl	89	25
Amoxicillin	Amoxicillin	88	58
Novolog Flexpen	Insulin Aspart	86	29
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	85	22
Meclizine Hcl	Meclizine Hcl	85	22
Duloxetine Hcl	Duloxetine Hcl	84	19
Oxybutynin Chloride Er	Oxybutynin Chloride	83	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	77	23
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	75	suppressed
Levetiracetam	Levetiracetam	75	13
Naproxen	Naproxen	75	21
Lorazepam	Lorazepam	73	19
Meloxicam	Meloxicam	71	18
Fenofibrate	Fenofibrate Nanocrystallized	70	suppressed
Nystatin	Nystatin	70	37
Ammonium Lactate	Ammonium Lactate	69	18
Dicyclomine Hcl	Dicyclomine Hcl	67	17
Vitamin D2	Ergocalciferol (Vitamin D2)	66	13
Metoclopramide Hcl	Metoclopramide Hcl	65	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	63	21
Tradjenta	Linagliptin	63	11
Finasteride	Finasteride	62	11
Gemfibrozil	Gemfibrozil	62	suppressed
Hydrocortisone	Hydrocortisone	62	13
Quetiapine Fumarate	Quetiapine Fumarate	62	17
Linzess	Linaclotide	61	12
Mounjaro	Tirzepatide	60	12
Topiramate	Topiramate	60	11
Clonazepam	Clonazepam	59	13
Amitriptyline Hcl	Amitriptyline Hcl	58	suppressed
Calcitriol	Calcitriol	58	13
Lactulose	Lactulose	58	21
Temazepam	Temazepam	58	suppressed
Bupropion Xl	Bupropion Hcl	57	14
Ezetimibe	Ezetimibe	57	13
Ibu	Ibuprofen	57	18
Spironolactone	Spironolactone	57	suppressed
Metformin Hcl Er	Metformin Hcl	55	14
Sumatriptan Succinate	Sumatriptan Succinate	55	suppressed
Olanzapine	Olanzapine	53	suppressed
Risperidone	Risperidone	52	11
Isosorbide Dinitrate	Isosorbide Dinitrate	51	suppressed
Brilinta	Ticagrelor	50	suppressed
Citalopram Hbr	Citalopram Hydrobromide	50	13
Celecoxib	Celecoxib	48	suppressed
Baclofen	Baclofen	47	16
Escitalopram Oxalate	Escitalopram Oxalate	47	20
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	47	suppressed
Alendronate Sodium	Alendronate Sodium	46	13
Entresto	Sacubitril/Valsartan	46	14
Hydroxyzine Hcl	Hydroxyzine Hcl	46	suppressed
Nifedipine Er	Nifedipine	46	12
Nitroglycerin	Nitroglycerin	45	12
Amiodarone Hcl	Amiodarone Hcl	44	17
Latanoprost	Latanoprost	44	12
Ondansetron Odt	Ondansetron	41	suppressed
Ropinirole Hcl	Ropinirole Hcl	41	13
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	40	16
Lidocaine	Lidocaine	40	13
Novolog	Insulin Aspart	40	suppressed
Pravastatin Sodium	Pravastatin Sodium	40	12
Sevelamer Carbonate	Sevelamer Carbonate	40	suppressed
Tizanidine Hcl	Tizanidine Hcl	40	12
Bumetanide	Bumetanide	39	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	39	31
Ketoconazole	Ketoconazole	39	13
Clonidine Hcl	Clonidine Hcl	37	suppressed
Lamotrigine	Lamotrigine	37	suppressed
Incruse Ellipta	Umeclidinium Bromide	36	suppressed
Memantine Hcl	Memantine Hcl	36	11
Tolterodine Tartrate	Tolterodine Tartrate	36	suppressed
Diltiazem Hcl	Diltiazem Hcl	35	suppressed
Myrbetriq	Mirabegron	35	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	35	suppressed
Trulicity	Dulaglutide	35	suppressed
Xarelto	Rivaroxaban	35	suppressed
Cephalexin	Cephalexin	34	25
Labetalol Hcl	Labetalol Hcl	34	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	33	23
Fluconazole	Fluconazole	33	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	13
Bupropion Hcl Sr	Bupropion Hcl	32	suppressed
Glipizide	Glipizide	32	suppressed
Rexulti	Brexpiprazole	32	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	31	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	31	11
Combivent Respimat	Ipratropium/Albuterol Sulfate	31	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Paroxetine Hcl	Paroxetine Hcl	30	suppressed
Benztropine Mesylate	Benztropine Mesylate	29	suppressed
Breo Ellipta	Fluticasone/Vilanterol	29	12
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	29	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	29	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Aripiprazole	Aripiprazole	28	suppressed
Digoxin	Digoxin	27	suppressed
Dutasteride	Dutasteride	27	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	27	suppressed
Farxiga	Dapagliflozin Propanediol	26	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	26	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	25	suppressed
Divalproex Sodium	Divalproex Sodium	25	suppressed
Loperamide	Loperamide Hcl	25	suppressed
Lovastatin	Lovastatin	25	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	25	suppressed
Spiriva Handihaler	Tiotropium Bromide	25	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	23	12
Trintellix	Vortioxetine Hydrobromide	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Humalog Kwikpen U-100	Insulin Lispro	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Midodrine Hcl	Midodrine Hcl	22	suppressed
Ofloxacin	Ofloxacin	22	21
Risperidone Er	Risperidone Microspheres	22	suppressed
Divalproex Sodium Er	Divalproex Sodium	21	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	21	suppressed
Sucralfate	Sucralfate	21	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	20	suppressed
Cefuroxime	Cefuroxime Axetil	20	18
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	20	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	16
Rybelsus	Semaglutide	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	19	suppressed
Nurtec Odt	Rimegepant Sulfate	19	suppressed
Sodium Chloride	0.9 % Sodium Chloride	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Clonidine	Clonidine	17	suppressed
Meloxicam	Meloxicam, Submicronized	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Ranolazine Er	Ranolazine	17	suppressed
Single Use Swab	Alcohol Antiseptic Pads	17	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	17	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	16	suppressed
Creon	Lipase/Protease/Amylase	16	suppressed
Ramipril	Ramipril	16	suppressed
Haloperidol	Haloperidol	15	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	15	suppressed
Primidone	Primidone	15	suppressed
Scopolamine	Scopolamine	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Valsartan	Valsartan	15	suppressed
Albuterol Sulfate	Albuterol Sulfate	14	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	14	suppressed
Haloperidol Lactate	Haloperidol Lactate	14	suppressed
Isosorbide Mononitrate	Isosorbide Mononitrate	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Abiraterone Acetate	Abiraterone Acetate	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	13	suppressed
Carvedilol Er	Carvedilol Phosphate	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Colesevelam Hcl	Colesevelam Hcl	13	suppressed
Epinephrine	Epinephrine	13	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	13	suppressed
Invokana	Canagliflozin	13	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	13	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	13	suppressed
Metronidazole	Metronidazole	13	12
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Sildenafil Citrate	Sildenafil Citrate	13	suppressed
Simbrinza	Brinzolamide/Brimonidine Tart	13	suppressed
Sodium Chloride	Sodium Chloride Irrig Solution	13	suppressed
Vraylar	Cariprazine Hcl	13	suppressed
Ceftriaxone	Ceftriaxone Sodium	12	suppressed
Clindamycin Hcl	Clindamycin Hcl	12	suppressed
Cyclosporine	Cyclosporine	12	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Repatha Sureclick	Evolocumab	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Vascepa	Icosapent Ethyl	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Ciclopirox	Ciclopirox Olamine	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Dilt-Xr	Diltiazem Hcl	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Minoxidil	Minoxidil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$1,029.95 · 35 records	CeQur Corporation	AIRSUPRA, CAPLYTA, CeQur Simplicity, ELIQUIS	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error